
Suven Life Sciences Q4 FY19 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Core CRAMS business expected to grow 10%-15% (Venkat Jasti, Page 14).
- Commercial CRAMS to increase from Rs. 80 crore to around Rs. 130 crore (Page 9).
- Specialty Chemicals expected to remain stable at Rs. 200-215 crore without significant growth (Page 4).
- Rising Pharma virtual company’s sales expected to start at $200 million and ramp up to $340-$360 million in 2-3 years (Page 6).
- New formulation manufacturing facility under construction, expected to add substantial revenue in 3-4 years (Page 11).
- For FY20, one or two commercial operations targeted in the formulation division (Page 16).
- CRAMS overall expected growth of 15%-20% (Page 9).
- Bottom-line guidance of 20% growth for FY20 standalone (Page 14,16).
See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.
Fundraise plans
NoSee what Suven Life Sciences management said on order book — free account, 30 seconds.
Capex plans
Yes- CAPEX guidance for FY20 is around Rs. 200 crore, primarily for new projects including the formulation development center and a new block in Vizag.
- Maintenance CAPEX is estimated at Rs. 30-40 crore based on requirements.
- The company is constructing a new formulation manufacturing facility expected to add substantial revenue 3-4 years from now.
- Rs. 35 million USD investment made upfront (day #1) for a 25% minority stake in Rising Pharma (Suven Shore), a virtual pharma company with about $200 million sales currently.
- This strategic investment aims to leverage ANDA development, manufacturing, and supply for future business growth.
- The investment is expected to create value over 5 years, with a potential 4x increase in valuation.
- Funding requirements including CAPEX and Rising Pharma investments are expected to be met through internal accruals, with minimal financing needs.
Track Suven Life Sciences — get its next earnings analysis in your feed
How does Suven Life Sciences rank vs peers in Healthcare Services?
Pro featureHow does Suven Life Sciences rank in Healthcare Services?
Compare Suven Life Sciences against every Healthcare Services company (Q4 FY19) on revenue, margins and earnings-call signals.
Continue your research
What Suven Life Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.